520-12-7
520-12-7
Chemical Structure
Pectolinarigenin
- CAS No.: 520-12-7
- Formula:C17H14O6
- Molecular Weight:314.29
IUPAC Name: 5,7-dihydroxy-6-methoxy-2-(4-methoxyphenyl)-4H-chromen-4-one
InChIKey: GPQLHGCIAUEJQK-UHFFFAOYSA-N
SMILES: O=C1C=C(C2=CC=C(OC)C=C2)OC3=CC(O)=C(OC)C(O)=C13
Biological Activity: Pectolinarigenin is an orally active dual inhibitor of COX-2/5-LOX with anti-inflammatory, antioxidant, antitumor and neuroprotective activities. Pectolinarigenin exerts neuroprotective and anti-inflammatory effects on astrocyte inflammation via the NFκB and MAPK pathways. Pectolinarigenin inhibits LPS-induced phosphorylation of ERK1/2, N-FκB and p38MAPK, directly inhibits the enzymatic activity or binding of COX-2, 5-LOX and HIF-1α, and reduces the level of XIAP. Pectolinarigenin modifies Keap1 to promote nuclear accumulation of Nrf2, induces ARE-mediated antioxidant enzyme expression, and possesses direct free radical scavenging activity. Pectolinarigenin reduces the release of NO, proinflammatory mediators and leukotrienes, and increases the level of IL-10. Pectolinarigenin induces G2/M cell cycle arrest, apoptosis (Apoptosis) and autophagy (Autophagy) via the PI3K/AKT/mTOR signaling pathway. Pectolinarigenin reduces renal crystal deposition and inhibits melanin synthesis. Pectolinarigenin inhibits inflammation and alleviates allergy in mouse models of inflammation. Pectolinarigenin alleviates renal injury, inflammation and oxidative stress in mice by inhibiting HIF-1α activity. Pectolinarigenin can be used for the research of neurodegenerative diseases, inflammatory/allergic diseases, calcium oxalate nephrocalcinosis, gastric cancer, melasma, post-inflammatory diseases and chloasma[1][2][3][4][5][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Pectolinarigenin | 99.98% | Pectolinarigenin is an orally active dual inhibitor of COX-2/5-LOX with anti-inflammatory, antioxidant, antitumor and neuroprotective activities. Pectolinarigenin exerts neuroprotective and anti-inflammatory effects on astrocyte inflammation via the NFκB and MAPK pathways. Pectolinarigenin inhibits LPS-induced phosphorylation of ERK1/2, N-FκB and p38MAPK, directly inhibits the enzymatic activity or binding of COX-2, 5-LOX and HIF-1α, and reduces the level of XIAP. Pectolinarigenin modifies Keap1 to promote nuclear accumulation of Nrf2, induces ARE-mediated antioxidant enzyme expression, and possesses direct free radical scavenging activity. Pectolinarigenin reduces the release of NO, proinflammatory mediators and leukotrienes, and increases the level of IL-10. Pectolinarigenin induces G2/M cell cycle arrest, apoptosis (Apoptosis) and autophagy (Autophagy) via the PI3K/AKT/mTOR signaling pathway. Pectolinarigenin reduces renal crystal deposition and inhibits melanin synthesis. Pectolinarigenin inhibits inflammation and alleviates allergy in mouse models of inflammation. Pectolinarigenin alleviates renal injury, inflammation and oxidative stress in mice by inhibiting HIF-1α activity. Pectolinarigenin can be used for the research of neurodegenerative diseases, inflammatory/allergic diseases, calcium oxalate nephrocalcinosis, gastric cancer, melasma, post-inflammatory diseases and chloasma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pectolinarigenin (Standard) | ≥98% | Pectolinarigenin (Standard) is the analytical standard of Pectolinarigenin. This product is intended for research and analytical applications. Pectolinarigenin is an orally active dual inhibitor of COX-2/5-LOX with anti-inflammatory, antioxidant, antitumor and neuroprotective activities. Pectolinarigenin exerts neuroprotective and anti-inflammatory effects on astrocyte inflammation via the NFκB and MAPK pathways. Pectolinarigenin inhibits LPS-induced phosphorylation of ERK1/2, N-FκB and p38MAPK, directly inhibits the enzymatic activity or binding of COX-2, 5-LOX and HIF-1α, and reduces the level of XIAP. Pectolinarigenin modifies Keap1 to promote nuclear accumulation of Nrf2, induces ARE-mediated antioxidant enzyme expression, and possesses direct free radical scavenging activity. Pectolinarigenin reduces the release of NO, proinflammatory mediators and leukotrienes, and increases the level of IL-10. Pectolinarigenin induces G2/M cell cycle arrest, apoptosis (Apoptosis) and autophagy (Autophagy) via the PI3K/AKT/mTOR signaling pathway. Pectolinarigenin reduces renal crystal deposition and inhibits melanin synthesis. Pectolinarigenin inhibits inflammation and alleviates allergy in mouse models of inflammation. Pectolinarigenin alleviates renal injury, inflammation and oxidative stress in mice by inhibiting HIF-1α activity. Pectolinarigenin can be used for the research of neurodegenerative diseases, inflammatory/allergic diseases, calcium oxalate nephrocalcinosis, gastric cancer, melasma, post-inflammatory diseases and chloasma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Acacetin (Standard) | 98.19% | Acacetin (Standard) is the analytical standard of Acacetin. This product is intended for research and analytical applications. Acacetin (5,7-Dihydroxy-4'-methoxyflavone) is an orally active flavonoid derived from Dendranthema morifolium. Acacetin docks in the ATP binding pocket of PI3Kγ. Acacetin causes cell cycle arrest and induces apoptosis and autophagy in cancer cells. Acacetin has potent anti-cancer and anti-inflammatory activity and has the potential for pain-related diseases research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Oroxylin A (Standard) | 99.25% | Oroxylin A (Standard) is the analytical standard of Oroxylin A. This product is intended for research and analytical applications. Oroxylin A is an active flavonoid compound with strong anti-cancer effects. Oroxylin A inhibits the IL-6/STAT3 pathway and NF-κB signaling, inhibits cell proliferation and induces apoptosis. Oroxylin A inhibits colitis-related carcinogenesis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Jaceosidin (Standard) | ≥98% | Jaceosidin (Standard) is the analytical standard of Jaceosidin. This product is intended for research and analytical applications. Jaceosidin is a flavonoid isolated from Artemisia vestita, induces apoptosis in cancer cells, activates Bax and down-regulates Mcl-1 and c-FLIP expression. Jaceosidin exhibits anti-cancer, anti-inflammatory activities, decreases leves of inflammatory markers, and suppresses COX-2 expression and NF-κB activation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Salvigenin (Standard) | ≥98% | Salvigenin is a natural polyphenolic compound, with neuroprotective effect. Salvigenin has antitumor cytotoxic and immunomodulatory properties. Salvigenin inhibits H2O2-induced cell apoptosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
5,6,7-Trihydroxy-4'-methoxyflavone | 5,6,7-Trihydroxy-4'-methoxyflavone (4'-O-Methylscutellarein) is a flavonoid and a weak inhibitor of xanthine oxidase. 5,6,7-Trihydroxy-4'-methoxyflavone possesses antithrombotic and antioxidant activities. 5,6,7-Trihydroxy-4'-methoxyflavone has an IC50 value of 25.29 µM for DPPH free radical scavenging. 5,6,7-Trihydroxy-4'-methoxyflavone can also inhibit H2O2-induced damage to PC12 cells. 5,6,7-Trihydroxy-4'-methoxyflavone is applicable for the research of diseases such as cerebrovascular disorders. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Hispidulin (Standard) | ≥98% | Hispidulin (Standard) is the analytical standard of Hispidulin. This product is intended for research and analytical applications. Hispidulin is a natural flavone with a broad spectrum of biological activities. Hispidulin is a Pim-1 inhibitor with an IC50 of 2.71 μM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
7,4'-Di-O-methylapigenin | 99.23% | 7,4'-Di-O-methylapigenin (4',7-Dimethoxy-5-Hydroxyflavone) is a flavonoid present in Lethedon tannaensis. 7,4'-Di-O-methylapigenin exhibits cytotoxicity against human nasopharyngeal carcinoma cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ladanein | 99.55% | Ladanein is a flavonoids compound isolated from Thymus piperella. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Demethoxycentaureidin | Demethoxycentaureidin (NSC 689466) is a natural product that can be isolated from Peucephyllum schottii. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cirsimaritin (Standard) | ≥98% | Cirsimaritin (Standard) is the analytical standard of Cirsimaritin (HY-N6648). This product is intended for research and analytical applications. Cirsimaritin binds weakly to the benzodiazepine site on GABAA receptors, with antidepressant, anxiolytic and antinociceptive activities. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Heimfarth L, et al. Neuroprotective and anti-inflammatory effect of pectolinarigenin, a flavonoid from Amazonian Aegiphila integrifolia (Jacq.), against lipopolysaccharide-induced inflammation in astrocytes via NFκB and MAPK pathways. Food Chem Toxicol. 2021;157:112538. [Content Brief]
- [2]. Lim H, et al. Anti-inflammatory activity of pectolinarigenin and pectolinarin isolated from Cirsium chanroenicum. Biol Pharm Bull. 2008;31(11):2063-2067. [Content Brief]
- [3]. Shiraiwa M, et al. Pectolinarigenin Induces Antioxidant Enzymes through Nrf2/ARE Pathway in HepG2 Cells. Antioxidants (Basel). 2022;11(4):675. Published 2022 Mar 30. [Content Brief]
- [4]. Yao R, et al. Pectolinarigenin alleviates calcium oxalate-induced renal inflammation and oxidative stress by binding to HIF-1α. Int Immunopharmacol. 2024;143(Pt 1):113284. [Content Brief]
- [5]. Lee HJ, et al. Pectolinarigenin Induced Cell Cycle Arrest, Autophagy, and Apoptosis in Gastric Cancer Cell via PI3K/AKT/mTOR Signaling Pathway. Nutrients. 2018;10(8):1043. Published 2018 Aug 8. [Content Brief]
- [6]. Lee S, et al. Pectolinarigenin, an aglycone of pectolinarin, has more potent inhibitory activities on melanogenesis than pectolinarin. Biochem Biophys Res Commun. 2017;493(1):765-772. [Content Brief]
